News/ News/ R&D/ Top stories AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics Phil Taylor AstraZeneca, cardiovascular disease, cholesterol, Dogma Therapeutics, licensing, PCSK9 inhibitors 0 Comment AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering Share X AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics https://pharmaphorum.com/news/az-buys-oral-pcsk9-cholesterol-drug-from-dogma-therapeutics/